November 28, 2017 / 11:47 AM / 19 days ago

BRIEF-Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

Nov 28 (Reuters) - Auris Medical Holding Ag:

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS

* AURIS MEDICAL HOLDING AG SAYS HEALOS TRIAL DID NOT MEET PRIMARY EFFICACY ENDPOINT IN OVERALL STUDY POPULATION

* AURIS MEDICAL SAYS IN HEALOS TRIAL, CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENT IN SUBPOPULATION OF PATIENTS WITH PROFOUND ACUTE HEARING LOSS

* AURIS MEDICAL SAYS BASED ON FINDINGS FROM HEALOS TRIAL, CONCLUDED THAT SIMILAR DESIGN OF ONGOING ASSENT TRIAL NO LONGER ADEQUATE FOR TESTING AM-111

* AURIS MEDICAL HOLDING AG SAYS BASED ON FINDINGS FROM HEALOS TRIAL, ASSENT TRIAL WILL BE TERMINATED EARLY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below